Application of Immunotherapy in the Gynecological Tumors
DOI:
https://doi.org/10.54097/gqtct139Keywords:
Immunotherapy; endometrial cancer; ovarian cancer; cervical cancer.Abstract
Gynecologic neoplasms refer to malignancies affecting the female reproductive system, including endometrial cancer, ovarian cancer, and cervical cancer. In recent years, there has been a consistent rise in the incidence of gynecological tumors in China. Due to its high mortality rate, this disease cannot be overlooked. Immunotherapy, which stimulates the body's immune cells to target and eliminate tumors, has emerged as a promising approach for treating gynecological cancers. The examples provided include endometrial cancer, ovarian cancer, and cervical cancer. Immunotherapy has gradually emerged as the primary or neoadjuvant treatment modality for endometrial cancer, exhibiting a remarkable potential to enhance patient survival and mitigate mortality risks. Immune checkpoint inhibitors have exhibited promising outcomes in ovarian cancer, with experimental evidence showcasing their therapeutic efficacy. Cervical cancer is currently exploring immunotherapy approaches and has made substantial progress, as evidenced by favorable response rates. This article provides an overview of current clinical methods and therapeutic outcomes associated with immunotherapy in gynecological cancer treatment while also exploring future directions for its development.
Downloads
References
[1] Clarke-Pearson, D. L., & Soper, J. (2010). Gynecological cancer management : identification, diagnosis and treatment (1st ed.). Wiley-Blackwell.
[2] Lee, S. M., Lee, S., Cho, H. W., Min, K. J., Hong, J. H., Song, J. Y., Lee, J. K., & Lee, N. W. (2023). Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors? International Journal of Molecular Sciences, 24(2), 974-. https://doi.org/10.3390/ijms24020974
[3] Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017). Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nature Reviews. Endocrinology, 13(4), 195–207. https://doi.org/10.1038/nrendo.2016.205
[4] Sasidharan Nair, V., & Elkord, E. (2018). Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells. Immunology and Cell Biology, 96(1), 21–33. https://doi.org/10.1111/imcb.1003
[5] Fan, C. T., Hsu, S. T., Sun, L., Hwang, S. F., Liu, C. K., Shih, Y. H., Chen, M. J., Li, H. N., Wang, J. S., Wen, M. C., & Lu, C. H. (2023). Improved Progression-Free Survival Associated with Tumor-Infiltrating Lymphocytes in High-Grade Endometrial Cancer. Journal of clinical medicine, 12(2), 603. https://doi.org/10.3390/jcm12020603
[6] Colombo, N., Lorusso, D., Santin, A., Kim, Y., Herráez, A., Yonemori, K., Fujiwara, K., Colomba, E., Miller, D., Pignata, S., Monk, B., Guerra, E., Kristeleit, R., Orlando, M., Sanli, U., Dutta, L., Orlowski, R., Ren, M., & Makker, V. (2021). 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). International Journal of Gynecological Cancer, 31(Suppl 3), A78–A78. https://doi.org/10.1136/ijgc-2021-ESGO.120
[7] Mariam, A., Kamath, S., Schveder, K., McLeod, H. L., & Rotroff, D. M. (2023). Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis. Oncology (Williston Park, N.Y.), 37(5), 210–219. https://doi.org/10.46883/2023.25920995
[8] Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019). Anti-CTLA-4 immunotherapy does not deplete Foxp3 regulatory T cells (Tregs) in human cancers. Clinical Cancer Research, 25(4), 1233–1238. https://doi.org/10.1158/1078-0432.CCR-18-0762
[9] Yano, M., Asami, Y., Nishikawa, T., Yoshida, S., Kamada, K., Katoh, T., Teramoto, Y., Nakamura, Y., & Yasuda, M. (2018). Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report. Medicine (Baltimore), 97(43), e12937-. https://doi.org/10.1097/MD.0000000000012937
[10] Friese, C., Harbst, K., Borch, T. H., Westergaard, M. C. W., Pedersen, M., Kverneland, A., Jönsson, G., Donia, M., Svane, I. M., & Met, Ö. (2020). CTLA-4 blockade boosts the expansion of tumor-reactive CD8 tumor-infiltrating lymphocytes in ovarian cancer. Scientific Reports, 10(1), 3914–3914. https://doi.org/10.1038/s41598-020-60738-4
[11] Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., Italiano, A., Kao, S., Piha-Paul, S. A., Delord, J.-P., McWilliams, R. R., Fabrizio, D. A., Aurora-Garg, D., Xu, L., Jin, F., … Bang, Y.-J. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncology, 21(10), 1353–1365. https://doi.org/10.1016/S1470-2045(20)30445-9
[12] Wendel Naumann, R., Hollebecque, A., Meyer, T., Michael-John Devlin, Oaknin, A., Kerger, J., Jose M. López-Picazo, Jean-Pascal Machiels, Jean-Pierre Delord, Thomas R.J. Evans, Boni, V., Calvo, E., Topalian, S. L., Chen, T., Soumaoro, I., Li, B., Gu, J., Zwirtes, R., & Moore, K. N. (2019). Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Jco, 37(31), 2825–2834. https://10.1200/JCO.19.00739
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
